The drug, called Arranon, is being granted approval for use in both adults and children under a fast track scheme based on less clinical data than is normally required, but the company must continue its studies to prove that it prolongs survival.
Initially, Arranon will be administered to those patients whose cancer has not responded to chemotherapy treatment or has relapsed.
The revenue of the leukemia treatment market has increased at a Compound Annual Growth Rate (CAGR) of 21% during the past eight years, due to the launch of new therapies including Sprycel (dasatinib), Tasigna (nilotinib), Clolar (cloferabine) and Arranon
(nelarabine), which will continue to enjoy patent protection throughout the next six years covered by the report's forecast period.
There was a small piece of good news for GlaxoSmithkline as FDA briefing documents concluded that its cancer drug Arranon
may offer benefits for treating rare kinds of blood cancer in some patients for whom chemotherapy has failed.
The moderate growth rate is primarily attributed to the patent expiry of Gleevec in 2015 in the US; 2016 in Europe, Clolar in 2015 in Europe and Arranon
in 2017 in US; 2013 in Europe.